The Conversion Price is subject to a one-time reset equal to the average of the daily VWAP for the three consecutive trading days immediately prior to the date that is 60 days after the First Closing Date, if such average is less than the Conversion Price in effect as of such date. Scilex intends to use the proceeds to enhance the commercialization of Scilex's three non-opioid pain management products for the treatment of acute and chronic pain. Scilex's suite of FDA-approved non-opioid pain management products include: "We are pleased to conclude this agreement with Yorkville, which will provide funding to expand ZTlido ® promotion worldwide and enhance the launch and commercialization of Gloperba ® and ELYXYB™.